ACR & Coalition Letters to Federal Policymakers

Rheumatology advocacy involves several branches of government and various agencies. ACR advocates to Congress, federal agencies, and others by writing or signing on to various policy letters.

2017 Federal Advocacy Letters

ACR Comments to CMS on Physician Fee Schedule 2018 Proposed Rule - 9/11/17

ACR Comments to CMS on Quality Payment Program Proposed Rule - 8/18/17

Coalition Letter on Local Coverage Determination Legislation (S. 794) - 7/11/17

ACR Comments to FDA Oncologic Drugs Advisory Committee - 7/10/17

ACR Response to CMS RFI on Regulatory Relief - 6/13/17

ACR Comments to FDA on Biosimilar Interchangeability Guidance - 5/19/17

ACR Letter on Notice of Information Collection Under OMB Emergency Review: Supplemental Questions for Visa Applicants - 5/18/17

Coalition Letter to Secretary Price on CMMI Reform Principles - 5/16/17

ACR Letter on American Health Care Act - 5/8/17

ACR Comments on McArthur Amendment to AHCA - 4/28/17

ACR Comments on CMS Proposals for Patient Condition Groups and Care Episode Groups - 4/24/17

ACR Letter on H1-B Visas and Physician Workforce - 4/17/17

ACR OP-ED on Workforce Challenges - 4/13/17

Coalition Letter on DXA - 3/24/17

ACR Statement on Congressional Efforts to Lower Specialty Drug Costs - 3/22/17

Coalition Letter to CMS on Physician Payment Programs - 3/21/2017

Coalition Letter on DoD Arthritis Research - 3/17/17

Coalition Letter on Cost Sharing - 3/7/17

ACR Letter to Congress on Healthcare Reform - 2/23/17

ACR Comments on ICER - 2/17/17

Coalition Letter on International Collaboration in Medicine - 2/8/17

Coalition Letter on FY17 NIH Funding - 2/7/17

Coalition Letter on IPAB Repeal - 1/24/17

2016 Federal Advocacy Letters

2015 Federal Advocacy Letters